Jan 9 |
Atea gains after mid-stage data for lead asset in Hepatitis C
|
Jan 8 |
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
|
Jan 3 |
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Nov 13 |
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
|
Nov 11 |
Atea Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
|
Nov 9 |
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript
|
Nov 9 |
Q3 2023 Atea Pharmaceuticals Inc Earnings Call
|
Nov 8 |
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
|
Nov 8 |
Atea Pharmaceuticals GAAP EPS of -$0.40
|
Nov 8 |
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
|